CareDx/$CDNA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CareDx
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Ticker
$CDNA
Sector
Primary listing
Employees
647
Headquarters
Website
CareDx Metrics
BasicAdvanced
$720M
13.56
$1.00
2.22
-
Price and volume
Market cap
$720M
Beta
2.22
52-week high
$31.13
52-week low
$10.96
Average daily volume
1.5M
Financial strength
Current ratio
3.298
Quick ratio
2.722
Long term debt to equity
6.958
Total debt to equity
8.896
Profitability
EBITDA (TTM)
-28.492
Gross margin (TTM)
66.91%
Net profit margin (TTM)
17.06%
Operating margin (TTM)
-12.51%
Effective tax rate (TTM)
0.53%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
-5.85%
Return on equity (TTM)
19.64%
Valuation
Price to earnings (TTM)
13.563
Price to revenue (TTM)
2.151
Price to book
2.2
Price to tangible book (TTM)
2.87
Price to free cash flow (TTM)
61.729
Free cash flow yield (TTM)
1.62%
Free cash flow per share (TTM)
0.219
Growth
Revenue change (TTM)
14.72%
Earnings per share change (TTM)
-131.75%
3-year revenue growth (CAGR)
2.68%
10-year revenue growth (CAGR)
27.96%
3-year earnings per share growth (CAGR)
-8.82%
10-year earnings per share growth (CAGR)
10.17%
What the Analysts think about CareDx
Analyst ratings (Buy, Hold, Sell) for CareDx stock.
Bulls say / Bears say
Persisting GAAP net loss of $10.35 million in Q1 2025 highlights ongoing unprofitability on a GAAP basis (Reuters).
Shares are down 15.3% since the start of the year despite recent operational progress, indicating continued market skepticism and valuation challenges (Reuters).
Natera's decision to appeal the overturned $96 million patent verdict extends legal uncertainty and potential costs for CareDx (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
CareDx Financial Performance
Revenues and expenses
CareDx Earnings Performance
Company profitability
CareDx News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CareDx stock?
CareDx (CDNA) has a market cap of $720M as of September 13, 2025.
What is the P/E ratio for CareDx stock?
The price to earnings (P/E) ratio for CareDx (CDNA) stock is 13.56 as of September 13, 2025.
Does CareDx stock pay dividends?
No, CareDx (CDNA) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next CareDx dividend payment date?
CareDx (CDNA) stock does not pay dividends to its shareholders.
What is the beta indicator for CareDx?
CareDx (CDNA) has a beta rating of 2.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.